Suparna C. Clasen

Suparna C. Clasen

Auto-generated profile, based on publicly available information

Suparna C. Clasen

Division of Cardiovascular Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
SCSuparna C. Clasen
Suparna C. Clasen
HSHaochang Shou
Haochang Shou
GFGary Freedman
Gary Freedman
JPJohn P. Plastaras
John P. Plastaras
NTNeil K. Taunk
Neil K. Taunk
BKBonnie Ky
Bonnie Ky

10 October 2021 in Cardio-Oncology
Verified
Journal Article
Open access
PDF file
SCSuparna C. Clasen
Suparna C. Clasen
PDPaul C. Dinh
Paul C. Dinh
LHLifang Hou
Lifang Hou
CFChunkit Fung
Chunkit Fung
HSHoward D. Sesso
Howard D. Sesso
LTLois B. Travis
Lois B. Travis
Significantly increased risks of cardiovascular disease occur in testicular cancer survivors given cisplatin-based chemotherapy. The postulated mechanism of platinum-based chemotherapy’s vascular toxicity has been thought secondary to its different early- and late- effects on vascular injury, endothelial dysfunction, and induction of a hypercoagulable state. We highlight for the first time the similarities between platinum-associated vascular adverse events and the vascular toxicity associated with other xenobiotic-metal contaminants. The vascular toxicity seen in large epidemiologic studies of testicular cancer survivors may in part be similar and mechanistically linked to the risk seen in environmental heavy metal contaminants linked to cardiovascular disease. Future research should be directed to better understand the magnitude of the adverse cardiovascular effects of platinum and to elucidate the underlying mechanisms of action.

26 March 2022 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
LVLaura B. Vater
Laura B. Vater
BLBénédicte Lefebvre
Bénédicte Lefebvre
ATAnita Turk
Anita Turk
SCSuparna C. Clasen
Suparna C. Clasen

3 March 2023 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
SCSuparna C. Clasen
Suparna C. Clasen
CFChunkit Fung
Chunkit Fung
HSHoward D. Sesso
Howard D. Sesso
LTLois B. Travis
Lois B. Travis

4 December 2024 in JACC: Case Reports
Verified
Journal Article
Open access
ABAditya V Belamkar
Aditya V Belamkar
MMMarwan Mounayar
Marwan Mounayar
SCSuparna C. Clasen
Suparna C. Clasen
An 85-year-old man with recently diagnosed metastatic EGFR+ lung adenocarcinoma treated with osimertinib presented after 1 month of therapy in decompensated congestive heart failure along with atrial fibrillation, prolonged QTc and acute kidney injury. Osimertinib was held. His hemodynamic status was optimized, and he was started on cardioprotective medications (losartan and metoprolol succinate), and LVEF recovered. However, after reintroducing osimertinib, LVEF reduced, indicating possible osimertinib-induced cardiomyopathy. An SGLT2 inhibitor was added for cardioprotection before another rechallenge of osimertinib. SGLT2 inhibitors are a powerful tool for heart failure and may have a potential secondary benefit in ameliorating cardiotoxic processes. Although their use in osimertinib-induced cardiomyopathy has not been well-established, current heart failure guidelines and emerging research support its use in this setting. This case and the accompanying literature review highlight the novel use of SGLT2 inhibitors coupled with regular clinical and imaging monitoring, as a compelling intervention for osimertinib-induced cardiomyopathy.

1 January 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SCSuparna C. Clasen
Suparna C. Clasen
MMMeagan Miller
Meagan Miller
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice.